Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging

NeuroImage

Volumn 60, Issue 4, 2012, Pages 2086-2095

  Aggarwal, Manisha ^a   Duan, Wenzhen ^a   Hou, Zhipeng ^a   Rakesh, Neal ^a   Peng, Qi ^a   Ross, Christopher A ^a   Miller, Michael I ^a   Mori, Susumu ^a,b   Zhang, Jiangyang ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

Brain atrophy; Huntington's disease; Longitudinal; Magnetic resonance imaging; Mouse

Indexed keywords

SERTRALINE; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MODEL; FRONTAL CORTEX; FUNCTIONAL DISEASE; HUNTINGTON CHOREA; IN VIVO STUDY; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

ANIMALS; ATROPHY; BRAIN; BRAIN MAPPING; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION;

EID: 84862806580     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.01.141     Document Type: Article

References (51)

1. Aggarwal M., Zhang J., Miller M.I., Sidman R.L., Mori S. Magnetic resonance imaging and micro-computed tomography combined atlas of developing and adult mouse brains for stereotaxic surgery. Neuroscience 2009, 162(4):1339-1350.
2. Ashburner J., Hutton C., Frackowiak R., Johnsrude I., Price C., Friston K. Identifying global anatomical differences: deformation-based morphometry. Hum. Brain Mapp. 1998, 6(5-6):348-357.
3. Aylward E.H., Anderson N.B., Bylsma F.W., Wagster M.V., Barta P.E., Sherr M., Feeney J., Davis A., Rosenblatt A., Pearlson G.D., Ross C.A. Frontal lobe volume in patients with Huntington's disease. Neurology 1998, 50(1):252-258.
4. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63(1):66-72.
5. Aylward E.H., Nopoulos P.C., Ross C.A., Langbehn D.R., Pierson R.K., Mills J.A., Johnson H.J., Magnotta V.A., Juhl A.R., Paulsen J.S. Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 2010, 82(4):405-410.
6. Aylward, E.H., Liu, D., Nopoulos, P.C., Ross, C.A., Pierson, R.K., Mills, J.A., Long, J.D., Paulsen, J.S., in press. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol. Psychiatry. DOI:. http://DOI:10.1016/j.biopsych.2011.07.030.
7. Beal M.F., Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 2004, 5(5):373-384.
8. Cheng Y., Peng Q., Hou Z., Aggarwal M., Zhang J., Mori S., Ross C.A., Duan W. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage 2011, 56(3):1027-1034.
9. Chuang N., Mori S., Yamamoto A., Jiang H., Ye X., Xu X., Richards L.J., Nathans J., Miller M.I., Toga A.W., Sidman R.L., Zhang J. An MRI-based atlas and database of the developing mouse brain. Neuroimage 2011, 54(1):80-89.
10. Dedeoglu A., Kubilus J.K., Yang L., Ferrante K.L., Hersch S.M., Beal M.F., Ferrante R.J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 2003, 85(6):1359-1367.
11. Duan W., Guo Z., Jiang H., Ladenheim B., Xu X., Cadet J.L., Mattson M.P. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann. Neurol. 2004, 55(4):590-594.
12. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., Zhao M., Cadet J.L., Wong J., Ross C.A. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 2008, 30(3):312-322.
13. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22(5):1592-1599.
14. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23(28):9418-9427.
15. Fitzmaurice G.M., Laird N.M., Ware J.H. Applied Longitudinal Analysis 2004, Wiley-IEEE.
16. Genovese C.R., Lazar N.A., Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002, 15(4):870-878.
17. Hersch S.M., Ferrante R.J. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 2004, 1(3):298-306.
18. Iannicola C., Moreno S., Oliverio S., Nardacci R., Ciofi-Luzzatto A., Piacentini M. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J. Neurochem. 2000, 75(2):830-839.
19. Jenkins B.G., Andreassen O.A., Dedeoglu A., Leavitt B., Hayden M., Borchelt D., Ross C.A., Ferrante R.J., Beal M.F. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J. Neurochem. 2005, 95(2):553-562.
20. Jevtovic-Todorovic V., Hartman R.E., Izumi Y., Benshoff N.D., Dikranian K., Zorumski C.F., Olney J.W., Wozniak D.F. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J. Neurosci. 2003, 23(3):876-882.
21. Jones B.J., Roberts D.J. The quantitative measurement of motor inco-ordination in naive mice using an accelerating rod. J. Pharm. Pharmacol. 1968, 20(4):302-304.
22. Kovacevic N., Henderson J.T., Chan E., Lifshitz N., Bishop J., Evans A.C., Henkelman R.M., Chen X.J. A three-dimensional atlas of the mouse brain with estimates of the average and variability. Cereb. Cortex 2005, 15(5):639-645.
23. Lau J.C., Lerch J.P., Sled J.G., Henkelman R.M., Evans A.C., Bedell B.J. Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. Neuroimage 2008, 42(1):19-27.
24. Lerch J.P., Carroll J.B., Spring S., Bertram L.N., Schwab C., Hayden M.R., Henkelman R.M. Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage 2008, 39(1):32-39.
25. Liang G., Ward C., Peng J., Zhao Y., Huang B., Wei H. Isoflurane causes greater neurodegeneration than an equivalent exposure of sevoflurane in the developing brain of neonatal mice. Anesthesiology 2010, 112(6):1325-1334.
26. Maheswaran S., Barjat H., Bate S.T., Aljabar P., Hill D.L., Tilling L., Upton N., James M.F., Hajnal J.V., Rueckert D. Analysis of serial magnetic resonance images of mouse brains using image registration. Neuroimage 2009, 44(3):692-700.
27. Maheswaran S., Barjat H., Rueckert D., Bate S.T., Howlett D.R., Tilling L., Smart S.C., Pohlmann A., Richardson J.C., Hartkens T., Hill D.L., Upton N., Hajnal J.V., James M.F. Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP×PS1 mice using MRI. Brain Res. 2009, 1270:19-32.
28. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506.
29. McDaniel B., Sheng H., Warner D.S., Hedlund L.W., Benveniste H. Tracking brain volume changes in C57BL/6J and ApoE-deficient mice in a model of neurodegeneration: a 5-week longitudinal micro-MRI study. Neuroimage 2001, 14(6):1244-1255.
30. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 2002, 23(1):32-39.
31. Miller M.I., Trouve A., Younes L. On the metrics and Euler-Lagrange equations of computational anatomy. Annu. Rev. Biomed. Eng. 2002, 4:375-405.
32. Paulsen J.S., Hayden M., Stout J.C., Langbehn D.R., Aylward E., Ross C.A., Guttman M., Nance M., Kieburtz K., Oakes D., Shoulson I., Kayson E., Johnson S., Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Arch. Neurol. 2006, 63(6):883-890.
33. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C.A., Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 2008, 210(1):154-163.
34. Pinheiro J.C., Bates D.M. Mixed Effects Models in S and S-Plus 2000, Springer.
35. Ramaswamy S., McBride J.L., Kordower J.H. Animal models of Huntington's disease. ILAR J. 2007, 48(4):356-373.
36. Roberts T.J., Price J., Williams S.C., Modo M. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience 2006, 139(4):1187-1199.
37. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10(1):83-98.
38. Sawiak S.J., Wood N.I., Williams G.B., Morton A.J., Carpenter T.A. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2009, 33(1):12-19.
39. Saydoff J.A., Garcia R.A., Browne S.E., Liu L., Sheng J., Brenneman D., Hu Z., Cardin S., Gonzalez A., von Borstel R.W., Gregorio J., Burr H., Beal M.F. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol. Dis. 2006, 24(3):455-465.
40. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8(3):397-407.
41. Schilling G., Coonfield M.L., Ross C.A., Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 2001, 315(3):149-153.
42. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490(4):354-370.
43. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., Del Signore S.J., Cudkowicz M.E., Friedlander R.M., Ferrante R.J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762(3):373-380.
44. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., Landwehrmeyer G.B., Fox N.C., Johnson H., Hicks S.L., Kennard C., Craufurd D., Frost C., Langbehn D.R., Reilmann R., Stout J.C. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2010, 10(1):31-42.
45. Toga A.W., Thompson P.M. Temporal dynamics of brain anatomy. Annu. Rev. Biomed. Eng. 2003, 5:119-145.
46. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(14):8093-8097.
47. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44(6):559-577.
48. Walker F.O. Huntington's disease. Lancet 2007, 369(9557):218-228.
49. Ward B.C., Agarwal S., Wang K., Berger-Sweeney J., Kolodny N.H. Longitudinal brain MRI study in a mouse model of Rett Syndrome and the effects of choline. Neurobiol. Dis. 2008, 31(1):110-119.
50. Wingert F. Biometrical analysis of growth functions of cerebral component parts and body weight. J. Hirnforsch. 1969, 11(1):133-197.
51. Zhang J., Peng Q., Li Q., Jahanshad N., Hou Z., Jiang M., Masuda N., Langbehn D.R., Miller M.I., Mori S., Ross C.A., Duan W. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 2009, 49(3):2340-2351.